Subscribe To
Candel therapeutics presents preclinical data from its enlighten™ discovery platform at sitc
The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immuno...
November 4, 2023, 12:00 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent ...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent ...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent ...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent ...
November 3, 2023, 11:30 pm
Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...
November 3, 2023, 8:30 pm
Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...
November 3, 2023, 8:30 pm
Sensei biotherapeutics reports favorable clinical data for sns-101 at 2023 sitc annual meeting
– Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potential...
November 3, 2023, 8:05 pm
Kineta reports third quarter 2023 financial results and provides corporate update
Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial...
November 3, 2023, 8:01 pm
New preliminary clinical data on potential of opus aav-based gene therapy for rare inherited retinal disease to be presented at the american academy of ophthalmology annual conference 2023
Data to be presented as part of gene augmentation therapy presentation RALEIGH, N.C., Nov. 03, 2023 (GL...
November 3, 2023, 7:43 pm
Taysha gene therapies: tsha-102's potential is a 'buy'
Taysha Gene Therapies is a biotech stock focused on developing gene therapies for monogenic CNS diseases, with its lead candidate TSHA-102 targeting R...
November 3, 2023, 7:41 pm
Cellectis: end of 2023 data readouts to boost car-t prospects
Preliminary data from two early-stage studies are going to be shown at the ASH 2023 conference, showcasing its cell ...
November 3, 2023, 6:57 pm
Coherus presents data from next-generation immuno-oncology programs at 38th annual meeting of society for immunotherapy of cancer (sitc)
– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development ...
November 3, 2023, 12:30 pm
Gilead to present late breaking data and real world evidence highlighting key hepatitis indications at the liver meeting® 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new viral hepatitis data at the America...
November 3, 2023, 11:00 am
Turnstone biologics presents preclinical data highlighting potential for selected tumor-infiltrating lymphocyte (til) therapy in solid tumors at the 2023 society for immunotherapy of cancer (sitc) ann
Presentations showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for t...
November 3, 2023, 10:00 am
Why crispr therapeutics stock charged northward this week
Gene therapy has been on a roller-coaster ride since the first patient was treated 33 years ago. This s...
November 3, 2023, 9:56 am
Poolbeg's lead asset to be in the spotlight at leading medical conference
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said the potential of its lead asset will be discussed at a leading medical conference in December. A poste...
November 3, 2023, 3:32 am
Helius medical technologies, inc. to release third quarter 2023 financial results on november 9, 2023; announces extended cash runway into q2 2024
-- Expects to report Q3 revenues in range of $140 - $150 thousand, reflecting the expected decrease in U.S. sales with the conclusion of the Patient <...
November 2, 2023, 5:05 pm
Siren biotechnology awarded $4m in grant funding from the california institute for regenerative medicine (cirm)
SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) — Siren Biotechnology, a gene therapy company pioneerin...
November 1, 2023, 4:46 pm
Lirum therapeutics presents positive data on lx-101, a novel clinical-stage targeted therapy, demonstrating potent preclinical activity against pediatric sarcomas
New York, NY, Oct. 31, 2023 (GLOBE NEWSWIRE) — Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focuse...
October 31, 2023, 5:27 pm